- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Dr. Reddy’s Laboratories has announced a board meeting on the financial results for the quarter and half-year. Consolidated revenues rose 20% YoY to ₹8,506 Cr in Q4 and 17% YoY to ₹32,553 Cr for FY25, led by Global Generics, Pharma Services, and the new Nicotine Replacement Therapy business. Q4 profit after tax increased 22% YoY to ₹1,594 Cr; FY25 profit grew 2% to ₹5,654 Cr. The Board approved a final dividend of ₹8 per share, enhancing shareholder returns, with the record date ahead of the AGM.